IN2014CH00393A - - Google Patents
Info
- Publication number
- IN2014CH00393A IN2014CH00393A IN393CH2014A IN2014CH00393A IN 2014CH00393 A IN2014CH00393 A IN 2014CH00393A IN 393CH2014 A IN393CH2014 A IN 393CH2014A IN 2014CH00393 A IN2014CH00393 A IN 2014CH00393A
- Authority
- IN
- India
- Prior art keywords
- peptide
- support
- adhesive layer
- cellular immunity
- tape preparation
- Prior art date
Links
- 239000012790 adhesive layer Substances 0.000 abstract 2
- 230000007969 cellular immunity Effects 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 239000000853 adhesive Substances 0.000 abstract 1
- 230000001070 adhesive effect Effects 0.000 abstract 1
- 229940022399 cancer vaccine Drugs 0.000 abstract 1
- 238000009566 cancer vaccine Methods 0.000 abstract 1
- 230000006698 induction Effects 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001152—Transcription factors, e.g. SOX or c-MYC
- A61K39/001153—Wilms tumor 1 [WT1]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4242—Transcription factors, e.g. SOX or c-MYC
- A61K40/4243—Wilms tumor 1 [WT1]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2013020798 | 2013-02-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
IN2014CH00393A true IN2014CH00393A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 2015-04-03 |
Family
ID=50028734
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN393CH2014 IN2014CH00393A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 2013-02-05 | 2014-01-29 |
Country Status (8)
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2626238C (en) | 2005-10-17 | 2015-10-06 | Sloan Kettering Institute For Cancer Research | Wt1 hla class ii-binding peptides and compositions and methods comprising same |
EP3117836A1 (en) | 2006-04-10 | 2017-01-18 | Sloan Kettering Institute For Cancer Research | Immunogenic wt-1 peptides and uses thereof |
EP3520810A3 (en) | 2012-01-13 | 2019-11-06 | Memorial Sloan-Kettering Cancer Center | Immunogenic wt1 peptides and use thereof |
CN116253788A (zh) | 2013-01-15 | 2023-06-13 | 纪念斯隆凯特林癌症中心 | 免疫原性wt-1肽和其使用方法 |
US10815273B2 (en) | 2013-01-15 | 2020-10-27 | Memorial Sloan Kettering Cancer Center | Immunogenic WT-1 peptides and methods of use thereof |
JP6512568B2 (ja) * | 2013-02-05 | 2019-05-15 | 日東電工株式会社 | 経皮投与用wt1ペプチド癌ワクチン組成物 |
KR20170055487A (ko) * | 2014-10-02 | 2017-05-19 | 닛토덴코 가부시키가이샤 | 경피 투여용 백신 의약 조성물 |
DE102015119789A1 (de) * | 2015-11-16 | 2017-05-18 | Denso-Holding Gmbh & Co. | Korrosionsschutzzusammensetzung umfassend Polyisobutylene |
US20240024444A1 (en) * | 2020-08-07 | 2024-01-25 | Medrx Co., Ltd. | Combined Preparation |
CN114712493B (zh) * | 2022-04-29 | 2024-05-28 | 华南理工大学 | 一种疫苗递送载体及其制备方法和应用 |
EP4608875A1 (en) * | 2022-10-28 | 2025-09-03 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. | Anti-wt1/hla antibodies and uses thereof |
Family Cites Families (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL105325A (en) | 1992-04-16 | 1996-11-14 | Minnesota Mining & Mfg | Immunogen/vaccine adjuvant composition |
US6303347B1 (en) | 1997-05-08 | 2001-10-16 | Corixa Corporation | Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors |
US6764840B2 (en) | 1997-05-08 | 2004-07-20 | Corixa Corporation | Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors |
US6113918A (en) | 1997-05-08 | 2000-09-05 | Ribi Immunochem Research, Inc. | Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors |
DE69940264D1 (de) | 1998-07-31 | 2009-02-26 | Int Inst Cancer Immunology Inc | Krebsantigene, basierend auf dem tumorunterdrückenden genprodukt wt1 |
IL127331A0 (en) | 1998-11-30 | 1999-09-22 | Yeda Res & Dev | Peptide-based vaccine for influenza |
RU2192884C2 (ru) * | 2000-11-09 | 2002-11-20 | Государственное учреждение Научно-исследовательский институт клинической иммунологии СО РАМН | Вакцина для стимуляции противоопухолевого иммунитета |
US20040109869A1 (en) * | 2001-03-19 | 2004-06-10 | Iomai Corporation | Transcutaneous immunostimulation |
DE60224508T2 (de) | 2001-03-22 | 2008-12-24 | International Institute of Cancer Immunology, Inc., Suita-shi | Wti-modifiziertes peptid |
US7553494B2 (en) * | 2001-08-24 | 2009-06-30 | Corixa Corporation | WT1 fusion proteins |
AU2003242305A1 (en) | 2002-06-12 | 2003-12-31 | Chugai Seiyaku Kabushiki Kaisha | Hla-a24-restricted cancer antigen peptide |
AU2003264514A1 (en) | 2002-09-20 | 2004-04-08 | Chugai Seiyaku Kabushiki Kaisha | Wt1 substitution peptides |
US20050215501A1 (en) * | 2003-10-24 | 2005-09-29 | Coley Pharmaceutical Group, Inc. | Methods and products for enhancing epitope spreading |
WO2005045027A1 (ja) | 2003-11-05 | 2005-05-19 | International Institute Of Cancer Immunology, Inc. | Wt1由来のhla−dr結合性抗原ペプチド |
US8562988B2 (en) * | 2005-10-19 | 2013-10-22 | Ibc Pharmaceuticals, Inc. | Strategies for improved cancer vaccines |
JP4887284B2 (ja) | 2004-03-15 | 2012-02-29 | デイビッド・ケイ・アール・カラオリス | 癌細胞の増殖を阻害するための、または癌細胞のアポトーシスを増大させるための方法 |
ATE462003T1 (de) | 2004-03-31 | 2010-04-15 | Int Inst Cancer Immunology Inc | Aus wt1 stammende krebsantigenpeptide |
DE102004049223A1 (de) | 2004-10-08 | 2006-04-20 | Johannes-Gutenberg-Universität Mainz | Zubereitung zum Impfen, Impfverfahren und Verwendung einer Impf-Zubereitung |
EP1782826A1 (en) | 2005-11-08 | 2007-05-09 | GBF Gesellschaft für Biotechnologische Forschung mbH | PQS and c-diGMP and its conjugates as adjuvants and their uses in pharmaceutical compositions |
ES2352855T3 (es) | 2005-11-30 | 2011-02-23 | International Institute Of Cancer Immunology, Inc. | Nuevos compuestos peptídicos del tumor de wilms. |
RU2435782C2 (ru) | 2006-02-22 | 2011-12-10 | Интернешнл Инститьют Оф Кэнсер Иммунолоджи, Инк. | Hla-a*3303-рестриктированный пептид wt1 и содержащая его фармацевтическая композиция |
US20080112974A1 (en) | 2006-09-08 | 2008-05-15 | Duotol Ab | Method for inducing mucosal humoral and cell-mediated immune responses by sublingual administration of antigens |
JP4925039B2 (ja) * | 2006-09-21 | 2012-04-25 | 日東電工株式会社 | 糖材料の調製方法ならびに糖材料、糖材料を含むマイクロニードルおよびマイクロニードルをそなえてなる経皮製剤 |
JP2008127277A (ja) * | 2006-11-16 | 2008-06-05 | Osaka Prefectural Hospital Organization | 免疫賦活化促進剤 |
EP2980219B1 (en) | 2006-12-28 | 2018-11-14 | International Institute of Cancer Immunology, Inc. | Hla-a*1101-restricted wt1 peptide and pharmaceutical composition comprising the same |
WO2008093772A1 (ja) * | 2007-01-31 | 2008-08-07 | Hisamitsu Pharmaceutical Co., Inc. | 経皮または経粘膜投与のためのアジュバントおよびこれを含む医薬製剤 |
WO2009046738A1 (en) * | 2007-10-09 | 2009-04-16 | Curevac Gmbh | Composition for treating lung cancer, particularly of non-small lung cancers (nsclc) |
AU2008332278C1 (en) * | 2007-12-05 | 2013-10-03 | International Institute Of Cancer Immunology, Inc. | Cancer vaccine composition |
EP2337795A2 (en) * | 2008-10-01 | 2011-06-29 | Dako Denmark A/S | Mhc multimers in cancer vaccines and immune monitoring |
US8552165B2 (en) * | 2008-12-09 | 2013-10-08 | Heather Davis | Immunostimulatory oligonucleotides |
AR076349A1 (es) | 2009-04-23 | 2011-06-01 | Int Inst Cancer Immunology Inc | Peptido auxiliar del antigeno del cancer |
WO2011046832A2 (en) * | 2009-10-12 | 2011-04-21 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Granulysin in immunotherapy |
EP2868325B1 (en) * | 2012-07-02 | 2017-11-01 | Sumitomo Dainippon Pharma Co., Ltd. | Transdermal cancer antigen peptide preparation |
JP6512568B2 (ja) | 2013-02-05 | 2019-05-15 | 日東電工株式会社 | 経皮投与用wt1ペプチド癌ワクチン組成物 |
RU2014102938A (ru) | 2013-02-05 | 2015-08-10 | Нитто Денко Корпорейшн | Композиция вакцины для трансдермального введения |
RU2014102945A (ru) | 2013-02-05 | 2015-08-10 | Нитто Денко Корпорейшн | Вакцинная композиция |
-
2014
- 2014-01-29 CA CA2841014A patent/CA2841014A1/en not_active Abandoned
- 2014-01-29 US US14/166,954 patent/US10195258B2/en active Active
- 2014-01-29 RU RU2014102937A patent/RU2697443C2/ru not_active IP Right Cessation
- 2014-01-29 JP JP2014014805A patent/JP6512569B2/ja active Active
- 2014-01-29 KR KR1020140011637A patent/KR102050931B1/ko not_active Expired - Fee Related
- 2014-01-29 IN IN393CH2014 patent/IN2014CH00393A/en unknown
- 2014-01-29 EP EP14000321.1A patent/EP2762156A1/en not_active Withdrawn
- 2014-01-29 CN CN201410042748.8A patent/CN103961305B/zh not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
KR20140100421A (ko) | 2014-08-14 |
KR102050931B1 (ko) | 2019-12-02 |
CN103961305B (zh) | 2019-10-18 |
RU2697443C2 (ru) | 2019-08-14 |
CA2841014A1 (en) | 2014-08-05 |
CN103961305A (zh) | 2014-08-06 |
RU2014102937A (ru) | 2015-08-10 |
US20140220105A1 (en) | 2014-08-07 |
EP2762156A1 (en) | 2014-08-06 |
JP2014169279A (ja) | 2014-09-18 |
JP6512569B2 (ja) | 2019-05-15 |
US10195258B2 (en) | 2019-02-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IN2014CH00393A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | ||
IN2014CH00396A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | ||
IN2014CH00391A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | ||
MX2018008346A (es) | Terapia de combinación de virus oncológico e inhibidor de punto de control. | |
UY34780A (es) | Vectores virales para el tratamiento de distrofia retiniana | |
CA2924268C (en) | Anti-alpha-synuclein antibodies and methods of use | |
IN2014CH00395A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | ||
CL2015002472A1 (es) | Como inhibidores de mutant idh-yl-oxazolidin-2-onas 3-pirimidin-4. | |
MY167716A (en) | Drive device | |
MX2015012326A (es) | Anticuerpos anti-crth2 y su uso. | |
MX357202B (es) | Composicion de particula tipo virus. | |
MX2016003876A (es) | Métodos y aparatos para suministrar moléculas a través de capas de tejidos. | |
SG10201805806RA (en) | Modulation of Structured Polypeptide Specificity | |
PH12012501550A1 (en) | Modified tuberculosis antigens | |
EP3150202A4 (en) | Drug carrier for tumour-specific targeted drug delivery and use thereof | |
IN2014DN05885A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | ||
PH12015501071A1 (en) | Combination therapy of anti-her3 antibodies | |
MY191539A (en) | Streptococcal vaccine | |
MX2015011837A (es) | Co-cristale de pirimetanil y tetracarboximida de ditiina seleccionada. | |
PH12015501854A1 (en) | Factor ix polypeptide formulations | |
MY165824A (en) | Induction Motor and Ceiling Fan Including the Same | |
IN2014CH00386A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | ||
IN2014CH00390A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | ||
EP3857574A4 (en) | Magnetic levitation | |
MX2016004573A (es) | Inhibidores de nsp4 y metodos de uso. |